pfizer glp 1 news scraps daily weight loss pill danuglipron after a liver injury Safety worries spur Pfizer to

When GLP-1 binds to receptors in the stomach and gastrointestinal tract, it delays the passage of food through the digestive system

doi: 10.3389/fphar.2026.1798309 Received 28 January 2026 Revised 27 February 2026 Accepted 28 February 2026 Published 26 March 2026 Volume 17 - 2026 Edited by Marcos Roberto De Oliveira, Federal University of Rio Grande do Sul, Brazil Reviewed by Maria Jos De Rosa, CONICET Baha Blanca, Argentina Shubham Teli, BVVS Hanagal Shri Kumareshwar College of Pharmacy, India Updates Copyright 2026 Juthi, Ansari, Ahmed, Khan, Seidel, Kumar, Kumari, McKillop, Abdel-Wahab and Flatt

Patel asserts that this approach allows for consistent absorption and delivery into the bloodstream, bypassing the digestive systems harsh environment and first-pass metabolism

At present, the small molecules segment holds the maximum share of the GLP-1 market

Most of our IV therapy treatments do not require a prescription

But these ingredients are relatively common in supplements, so its not anything alarming